Subsequently, we evaluated the extent of the inhibition of VEGF functions by axitinib and sorafenib as VEGF inhibitors and its effect on the survival rate of lung cancer cells with high VEGF-A expression45. The gene discussed is VEGFA; the disease is lung carcinoma.